+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Anti-Infective Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2035

  • PDF Icon

    Report

  • 150 Pages
  • November 2026
  • Region: Global
  • Lucintel
  • ID: 6293484
The global anti-infective vaccine market is expected to reach an estimated $93.6 billion by 2035 from $68.3 billion in 2027 with a CAGR of 4.2% from 2027 to 2035. The major drivers for this market are the rising prevalence of infectious diseases, increased awareness about vaccination, and expansion of vaccine supply chains.

The future of the global anti-infective vaccine market looks promising with opportunities in the bacterial diseases and viral diseases markets.
  • Within the type category, conjugate vaccines is expected to witness the highest growth over the forecast period due to better immune responses elicited by new conjugate vaccine formulations, as compared to older vaccine formulations.
  • Within the application category, viral diseases is expected to witness the higher growth over the forecast period due to increased incidences of viral disease outbreaks are sustained by growing demand for vaccinations around the world.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to extensive population growth and increasing immunization programmed across the Asia Pacific region.

Emerging Trends in Anti-Infective Vaccine Market

In the 2025 to 2027 period, anti-infective vaccine markets will shift from episodic immunization to continuous prevention. Beyond childhood program demand, further diversification will be driven by public-health procurement, adult vaccination, improved surveillance and platform technologies. Lucintel believes profitability may be maximized when manufacturers can produce vaccines that are durable and scalable with efficacy geared toward middle-income countries.
  • Sustainability: In 2025 GSK set new manufacturing lower carbon goals that will likely influence future public tenders, as environmental criteria for all procurement are expected to be started by governments around the world in the next 3-5 years. Vaccine producers are also expected to follow manufacturing trends to reduce energy, water, and packaging.
  • Platform Manufacturing: MRNA and viral vector technologies are also being used in response to infectious diseases such as flu and tuberculosis, etc. Flexible platforms will help shorten the time to develop vaccines in response to new emerging infectious diseases.
  • Adult Immunization: WHO also called for more life-course vaccinations in October 2025. While focus in 2025 was on Adult vaccination for RSV and Shingles, in the aging societies and with the prevention funding of employers, adult vaccination is predicted to be a greater and more consistent revenue stream in the next decade.
  • Regional Supply Diversification: Gavi's 2025 to 2030 strategy includes manufacturing and procurement of vaccines in Africa and other developing countries as well as increasing vaccine exports by India. This will create a less concentrated supply and be more responsive to changing needs during epidemics.
  • Thermostable and Combination Vaccines: Products backed by WHO continue to focus on the development of formulations that allow temperature excursions and combination vaccines which help reduce injections and clinic visits. These products will help increase vaccine coverage in rural locations and decrease costs in the next three to five years.
The prevention-led, platform-driven, and more global market will be less reliant on large, one-time launches and more reliant on stable supply, adult uptake, flexible production, and optimal delivery systems. Manufacturers who balance evolving clinical innovations with procurement needs will gain market share. For the time being, access remains the most important factor, especially in locations where cold-chain concerns and low public funding still affect decision-making regarding vaccination.

Recent Developments in the Anti-Infective Vaccine Market

The anti-infective vaccine market is transitioning from a focus on the pandemic towards broader, targeted prevention. During 2025-2027, intense activity will continue as manufacturers increase capacity, regulators speed up pre-market approvals, and governments set up routine vaccination systems. In light of this, Lucintel should expand its market view to include procurement resilience, platform innovation, and access economics in addition to primary vaccine launches.
  • Combination Vaccine Approvals: GSK received FDA approval for Penmenvy in February 2025, becoming the first meningococcal vaccine to provide protection against the five serogroups. This improves compliance, simplifies schedules, and increases market competition within the adolescent and young adult vaccination market in the next 3-5 years.
  • New Pathogen Protection: FDA approved VIMKUNYA in February 2025 as the first chikungunya vaccine and is available for individuals 12 and older in the U.S. With demand for travel and military vaccines expected to increase because of likely climate change, the creation of this new vaccine market has commercially positioned this vaccine.
  • Malaria Procurement Expansion: Gavi’s goal of delivering 40 million malaria vaccine doses by the end of 2026 is expected to create a market and drive more suppliers to invest in additional malaria vaccine manufacturing.
  • Platform-led Pipeline Investment: Moderna stated in June 2025 that their respiratory vaccine program included six advanced resources that included combinational vaccines as well as COVID-19 and influenza vaccines. Like Moderna, other companies may adopt this philosophy to compete in the anti-infective vaccine market.
  • Regional Manufacturing Build-out: In April 2025, Biological E announced plans to increase vaccine production by 50% over the following two years. Increasing regional supply reduces reliance on global concentrated production and enhances tender competition in Asia, Africa, and Latin America.
These developments signify a market diminishing in emergency response and increasing in the breadth of portfolio, manufacturing discipline, and public health purchasing power. Additional commercial opportunities include combination products and travel vaccines. Malaria and routine immunization programs provide volume. In the next five years, winning suppliers will include the differentiated science of manufacturing, efficacy, and accessibility in the emerging markets.

Strategic Growth Opportunities in the Anti-Infective Vaccine Market

Between 2024 and 2026, the anti-infective vaccine market goes beyond routine childhood vaccination due to the surging demand caused by antimicrobial resistance, aging, travel and climate related trends. Public funds are increasing, while private actors are focused on differentiated products. Lucintel analyzes market segments where clinical value, convenience of administration and procurement economics comes together.
  • Expand Adult and Older-adult Vaccination: Pharmacies and employer sponsored clinics can provide vaccinations for pneumococcal disease, shingles, influenza, and respiratory vaccines. In May 2025, Gavi reported a US$11.9 billion funding requirement for its 2026-2030 strategy. Adult immunization will contribute to revenues as health care systems shift preventive care to vulnerable populations.
  • AMR Targeted Vaccines: Vaccines against pathogens such as extraintestinal E. coli and Klebsiella will help reduce the use of antibiotics and save on hospital costs. CEO WHO included antimicrobial resistance on the list of the top 10 health threats in February 2025. Decision makers will appreciate the value of vaccines that reduce the use of antibiotics, and will support higher prices and greater hospital adoption.
  • Vaccines for Climate Sensitive Diseases: New demand for vaccination will be driven by travel related climate change and changes in the climate for diseases like dengue, chikungunya, malaria and others. WHO reported 263 million cases of malaria in its 2023 report that was published in December 2024. During the next 3-5 years, changes in transmission zones will create demand for vaccination in countries without a vaccination program.
  • Development of Thermostable and Simplified Delivery Vaccines: Products that stay stable at elevated temperatures can be delivered to rural clinics. The scale of the cold chain dependency was highlighted by the approximately 2.7 billion vaccines procured by UNICEF in 2024. Until the current and future formulations of vaccines improve, there is business opportunity to create thermostable (stable at elevated temperatures) and reduced wastage versions of vaccines that can improve distribution economics.
  • Regional Manufacturing Partnerships: Local fill-finish and antigen production may improve vaccine supply security and help in winning government tenders. As reported by Africa CDC, in 2021, Africa depended on imports for 99% of its vaccines. Technology transfer agreements will matter more as governments impose local content conditions to their long-term purchase contracts.
Prevention Will Become A Procurement Focus Rather than A Limited Public Health Investment. The First Movers Will Be those Able To Integrate The Research Showing The Value of Avoided Infections with Successful Delivery Models. Adult, Climate Change Driven Demand, and Regional Production Are The Most Obvious Opportunities with The Rest of the World. Price Restraint Remains Important: Increasingly buyers are preferring outcomes that are measurable, reliable, and low cost to high tech.

Anti-Infective Vaccine Market Drivers and Challenges

Growth in the anti-infective vaccine market is a result of various factors including technology, diseases as well as public health priority, economy, and policy. Market growth is positively influenced by increasing demand, but is limited by affordability, production capacity, and inequitable distribution. Lucintel evaluates the market’s influences on investment, product development and competitive positioning.

The factors responsible for driving this market include:

  • Increasing Disease Burden: Threats like a resurgence of tuberculosis and the development of resistance to antimicrobials, have resulted in high global demand for preventive vaccines. According to the World Health Organization, in 2023 more than 10 million cases of tuberculosis were reported with a need for adequate immunization strategies. For the next 3-5 years there will be continued risk for infectious diseases and this will be a driver for governments and healthcare systems to prioritize vaccination and increase investment for vaccines to combat neglected, bacterial, viral, and respiratory diseases.
  • Improved Technology: Enhancements in vaccine technology like adjuvants, thermostable vaccine formulations, and messenger RNA and viral vector vaccine technologies are improving the speed and efficacy of vaccine development. In May 2025, the World Health Organization reported that more than 70 countries had expressed interest in establishing or enhancing their mRNA vaccine production. These technologies can considerably shorten development time, create the ability for rapid response to new outbreaks and facilitate multiple vaccine formulations, making them key growth accelerators in the anti-infective vaccine market for the next 3 to 5 years.
  • Regulatory and Public-Health Support: Demand continues to increase with the creation of governmental vaccination programs, accelerated approval pathways, procurement agreements, and global disease eradication initiatives. In September 2025, the United States Centers for Disease Control and Prevention predicted that routine childhood vaccination could stem around 14 million cases in the country, annually. In the next three to five years, public-sector purchasing and supportive policies will decrease the commercialization risk and encourage manufacturers to open and increase their vaccine production.
  • Expanding Adult and Travel Immunization: Beyond routine childhood vaccination, adult boosters and selection for occupational and travel medicine vaccination will become an increasingly larger market. As international travel continues to increase, an aging population, and the expansion of workplace health requirements will add to market demand for prevention vaccines.
  • Manufacturing and Distribution Efficiency: Automation and process control in rapidly evolving regional production and cold-chain logistics have increased manufacturing reliability. In April 2025, Gavi reported that more than 100 nations relied on zero-dose child coverage to evaluate and improve immunization access, thus the importance of efficient delivery. The next three to five years will see increased manufacturing and distribution that will decrease waste and increase flexibility to better serve previously unmet markets.

The challenges facing this market include:

  • High Costs and Complex Regulations: Clinical tests and safety studies, as well as quality and regulatory reviews, elongate the process of researching vaccines and leave researchers with a long and costly endeavor. In 2024, the World Health Organization found that the world’s vaccine research and development pipelines for vaccines against many different infectious diseases had more than a hundred candidates, which further intensified competition for funding and Availability of trials. During the next three to five years, expensive development programs and varying country’s regulations will cause delays and make market entry even harder for small companies. It will lead to a dependence on partnerships, grants, and governments.
  • Unequal Access and Affordability: Low-middle income countries and regions still have poor access and especially poor affordability of healthcare and weak vaccine delivery infrastructures, poor budgets, and inconsistent procurement. With 2023 data from UNICEF, it was found that almost 14.5 million children did not receive any vaccinations. During the next three to five years, demand will increase due to a lack of supply, and unequal distribution capacity will cause unequal market penetration, unless manufacturers, financing organizations, and governments create more affordable (or cheaper) options and increase their financial, innovative, local production, last mile delivery, and immunization services.
  • Supply Chain Challenges and Vaccine Hesitancy: Depending on confidence and quitting vaccinations leads to a loss of public trust and confidence, thus an inability to deliver vaccinations. In 2024, the World Health Organization found that vaccine misinformation was a large obstacle to public vaccinations and confidence. During the next three to five years demand may be high which means rapid changes in the supply of vaccinations and cost of inventory due to geopolitical disruptions, misinformation and changes in public attitudes. Vaccine manufacturers will need to focus on rapid regional sourcing of supplies and services and improving their communications and emergency response.
The anti-infective vaccine market will continue to grow in the foreseeable future with the increase in disease risk, adult vaccinations, and advancements in the technology and public-health funding. There are challenges like high entry costs, unfair distribution, supply shortages, complex regulation, and apathy. These challenges may slow down the market and create inequities across the globe. Innovations that are affordable and flexible manufacturing and distribution systems, in concert with a stronger collaboration from governments, healthcare services, research, and manufacturing sectors, will lower the barriers to enter the market. More technologies that are flexible enough to meet evolving needs and behaviors and are combined with efficient and evidence-based production and distribution systems will likely control the emerging market. The market is poised for growth in the future. The access to the market will be more equitable and the infrastructure green. The future looks bright for the market.

List of Anti-Infective Vaccine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies anti-infective vaccine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the anti-infective vaccine market companies profiled in this report include:

  • Emergent Biodefense Operations Lansing Inc.
  • Sanofi Pasteur
  • Merck & Co.
  • MedImmune LLC
  • Novartis Vaccines & Diagnostics Ltd.
  • Intercell Biomedical
  • MassBiologics
  • Barr Labs
  • Organon Teknika Co.

Anti-Infective Vaccine Market by Segment

The study includes a forecast for the global anti-infective vaccine market by type, application, and region.

Type [Value ($B) from 2019 to 2035]:

  • Inactivated Vaccines
  • Conjugate Vaccines
  • Live/Attenuated Vaccines

Application [Value ($B) from 2019 to 2035]:

  • Bacterial Diseases
  • Viral Diseases

Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Anti-Infective Vaccine Market

The anti-infective vaccine market will continue to change because of Public procurements, regional manufacturing, and platform investments through 2025 to 2027. As governments invest in preparedness for potential pandemics, so do vaccine manufacturers by either investing in mRNA, viral-vector platforms, or recombinant technologies. As per the latest analysis by Lucintel, these aforementioned market disruptions are proving to be pivotal.
  • United States: After HHS awarded Moderna a $590 million grant in January 2025 to further develop and commercialize mRNA based flu vaccines, the U.S.'s focus on pandemic flu shifted to the investment of mRNA-based flu vaccines. The grant allows for the advanced manufacturing of flu vaccines to meet the domestic demand shortened production timelines for the next three to five years.
  • China: With procurement and manufacturing control of technologies, CanSino Biologics focused in 2025 on holding existing large scale, recombinant, and mRNA vaccine commercial manufacturing platforms while developing technology. Domestically, China’s supply of vaccines are secure, allowing for extensive export capacity over the next three to five years.
  • Germany: With the Munich BioNTech headquarters and its European Research infrastructure, vaccine development and production Manufacturing were all maintained in 2025. Infectious disease platforms with continued platform investments will uphold Germany’s role in high-value vaccine development and improve regional production resilience through 2030.
  • India: The Indian government's proposed INR 99,858 crore health budget for 2025 integrated public health manufacturing and immunization systems. The Serum Institute and Bharat Biotech continued to produce and develop vaccines, both domestically and internationally. Government funding and large scale vaccine manufacturing will likely enhance Indias's position as a cost effective supplier in the next 3 to 5 years.
  • Japan: In 2025, the Japanese government continued to fund the preparations for future pandemics as well as domestic vaccine manufacturing, and included support for facilities and research under its strategic vaccine development framework. Public funding of domestic infrastructure and the investments of KM Biologics and Daiichi Sankyo will improve supply and create market opportunities for locally developed products in the next 3 to 5 years.

Features of the Global Anti-Infective Vaccine Market

  • Market Size Estimates: anti-infective vaccine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: anti-infective vaccine market size by type, application, and region in terms of value ($B).
  • Regional Analysis: anti-infective vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the anti-infective vaccine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the anti-infective vaccine market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the anti-infective vaccine market by type (inactivated vaccines, conjugate vaccines, and live/attenuated vaccines), application (bacterial diseases and viral diseases), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.1 Global Anti-Infective Vaccine Market Trends and Forecast
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Anti-Infective Vaccine Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Inactivated Vaccines: Trends and Forecast (2019-2035)
4.4 Conjugate Vaccines: Trends and Forecast (2019-2035)
4.5 Live/attenuated Vaccines: Trends and Forecast (2019-2035)
5. Global Anti-Infective Vaccine Market by Application
5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Bacterial Diseases: Trends and Forecast (2019-2035)
5.4 Viral Diseases: Trends and Forecast (2019-2035)
6. Regional Analysis
6.1 Overview
6.2 Global Anti-Infective Vaccine Market by Region
7. North American Anti-Infective Vaccine Market
7.1 Overview
7.2 North American Anti-Infective Vaccine Market by Type
7.3 North American Anti-Infective Vaccine Market by Application
7.4 United States Anti-Infective Vaccine Market
7.5 Mexican Anti-Infective Vaccine Market
7.6 Canadian Anti-Infective Vaccine Market
8. European Anti-Infective Vaccine Market
8.1 Overview
8.2 European Anti-Infective Vaccine Market by Type
8.3 European Anti-Infective Vaccine Market by Application
8.4 German Anti-Infective Vaccine Market
8.5 French Anti-Infective Vaccine Market
8.6 Spanish Anti-Infective Vaccine Market
8.7 Italian Anti-Infective Vaccine Market
8.8 United Kingdom Anti-Infective Vaccine Market
9. APAC Anti-Infective Vaccine Market
9.1 Overview
9.2 APAC Anti-Infective Vaccine Market by Type
9.3 APAC Anti-Infective Vaccine Market by Application
9.4 Japanese Anti-Infective Vaccine Market
9.5 Indian Anti-Infective Vaccine Market
9.6 Chinese Anti-Infective Vaccine Market
9.7 South Korean Anti-Infective Vaccine Market
9.8 Indonesian Anti-Infective Vaccine Market
10. RoW Anti-Infective Vaccine Market
10.1 Overview
10.2 RoW Anti-Infective Vaccine Market by Type
10.3 RoW Anti-Infective Vaccine Market by Application
10.4 Middle Eastern Anti-Infective Vaccine Market
10.5 South American Anti-Infective Vaccine Market
10.6 African Anti-Infective Vaccine Market
11. Competitor Analysis
11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter’s Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
11.4 Market Share Analysis
12. Opportunities & Strategic Analysis
12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
12.2.1 Growth Opportunities by Type
12.2.2 Growth Opportunities by Application
12.3 Emerging Trends in the Global Anti-Infective Vaccine Market
12.4 Strategic Analysis
12.4.1 New Product Development
12.4.2 Certification and Licensing
12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures
13. Company Profiles of the Leading Players Across the Value Chain
13.1 Competitive Analysis
13.2 Emergent Biodefense Operations Lansing Inc.
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.3 Sanofi Pasteur
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.4 Merck & Co.
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.5 Medimmune LLC
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.6 Novartis Vaccines
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.7 Diagnostics Ltd.
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.8 Intercell Biomedical
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.9 Massbiologics
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.10 Barr Labs
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
13.11 Organon Teknika Co
  • Company Overview
  • Anti-Infective Vaccine Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
14. Appendix
14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us
List of Figures
Chapter 1
Figure 1.1: Trends and Forecast for the Global Anti-Infective Vaccine Market
Chapter 2
Figure 2.1: Usage of Anti-Infective Vaccine Market
Figure 2.2: Classification of the Global Anti-Infective Vaccine Market
Figure 2.3: Supply Chain of the Global Anti-Infective Vaccine Market
Chapter 3
Figure 3.1: Driver and Challenges of the Anti-Infective Vaccine Market
Figure 3.2: PESTLE Analysis
Figure 3.3: Patent Analysis
Figure 3.4: Regulatory Environment
Chapter 4
Figure 4.1: Global Anti-Infective Vaccine Market by Type in 2019, 2026, and 2035
Figure 4.2: Trends of the Global Anti-Infective Vaccine Market ($B) by Type
Figure 4.3: Forecast for the Global Anti-Infective Vaccine Market ($B) by Type
Figure 4.4: Trends and Forecast for Inactivated Vaccines in the Global Anti-Infective Vaccine Market (2019-2035)
Figure 4.5: Trends and Forecast for Conjugate Vaccines in the Global Anti-Infective Vaccine Market (2019-2035)
Figure 4.6: Trends and Forecast for Live/attenuated Vaccines in the Global Anti-Infective Vaccine Market (2019-2035)
Chapter 5
Figure 5.1: Global Anti-Infective Vaccine Market by Application in 2019, 2026, and 2035
Figure 5.2: Trends of the Global Anti-Infective Vaccine Market ($B) by Application
Figure 5.3: Forecast for the Global Anti-Infective Vaccine Market ($B) by Application
Figure 5.4: Trends and Forecast for Bacterial Diseases in the Global Anti-Infective Vaccine Market (2019-2035)
Figure 5.5: Trends and Forecast for Viral Diseases in the Global Anti-Infective Vaccine Market (2019-2035)
Chapter 6
Figure 6.1: Trends of the Global Anti-Infective Vaccine Market ($B) by Region (2019-2026)
Figure 6.2: Forecast for the Global Anti-Infective Vaccine Market ($B) by Region (2027-2035)
Chapter 7
Figure 7.1: North American Anti-Infective Vaccine Market by Type in 2019, 2026, and 2035
Figure 7.2: Trends of the North American Anti-Infective Vaccine Market ($B) by Type (2019-2026)
Figure 7.3: Forecast for the North American Anti-Infective Vaccine Market ($B) by Type (2027-2035)
Figure 7.4: North American Anti-Infective Vaccine Market by Application in 2019, 2026, and 2035
Figure 7.5: Trends of the North American Anti-Infective Vaccine Market ($B) by Application (2019-2026)
Figure 7.6: Forecast for the North American Anti-Infective Vaccine Market ($B) by Application (2027-2035)
Figure 7.7: Trends and Forecast for the United States Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 7.8: Trends and Forecast for the Mexican Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 7.9: Trends and Forecast for the Canadian Anti-Infective Vaccine Market ($B) (2019-2035)
Chapter 8
Figure 8.1: European Anti-Infective Vaccine Market by Type in 2019, 2026, and 2035
Figure 8.2: Trends of the European Anti-Infective Vaccine Market ($B) by Type (2019-2026)
Figure 8.3: Forecast for the European Anti-Infective Vaccine Market ($B) by Type (2027-2035)
Figure 8.4: European Anti-Infective Vaccine Market by Application in 2019, 2026, and 2035
Figure 8.5: Trends of the European Anti-Infective Vaccine Market ($B) by Application (2019-2026)
Figure 8.6: Forecast for the European Anti-Infective Vaccine Market ($B) by Application (2027-2035)
Figure 8.7: Trends and Forecast for the German Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 8.8: Trends and Forecast for the French Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 8.9: Trends and Forecast for the Spanish Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 8.10: Trends and Forecast for the Italian Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 8.11: Trends and Forecast for the United Kingdom Anti-Infective Vaccine Market ($B) (2019-2035)
Chapter 9
Figure 9.1: APAC Anti-Infective Vaccine Market by Type in 2019, 2026, and 2035
Figure 9.2: Trends of the APAC Anti-Infective Vaccine Market ($B) by Type (2019-2026)
Figure 9.3: Forecast for the APAC Anti-Infective Vaccine Market ($B) by Type (2027-2035)
Figure 9.4: APAC Anti-Infective Vaccine Market by Application in 2019, 2026, and 2035
Figure 9.5: Trends of the APAC Anti-Infective Vaccine Market ($B) by Application (2019-2026)
Figure 9.6: Forecast for the APAC Anti-Infective Vaccine Market ($B) by Application (2027-2035)
Figure 9.7: Trends and Forecast for the Japanese Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 9.8: Trends and Forecast for the Indian Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 9.9: Trends and Forecast for the Chinese Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 9.10: Trends and Forecast for the South Korean Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 9.11: Trends and Forecast for the Indonesian Anti-Infective Vaccine Market ($B) (2019-2035)
Chapter 10
Figure 10.1: RoW Anti-Infective Vaccine Market by Type in 2019, 2026, and 2035
Figure 10.2: Trends of the RoW Anti-Infective Vaccine Market ($B) by Type (2019-2026)
Figure 10.3: Forecast for the RoW Anti-Infective Vaccine Market ($B) by Type (2027-2035)
Figure 10.4: RoW Anti-Infective Vaccine Market by Application in 2019, 2026, and 2035
Figure 10.5: Trends of the RoW Anti-Infective Vaccine Market ($B) by Application (2019-2026)
Figure 10.6: Forecast for the RoW Anti-Infective Vaccine Market ($B) by Application (2027-2035)
Figure 10.7: Trends and Forecast for the Middle Eastern Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 10.8: Trends and Forecast for the South American Anti-Infective Vaccine Market ($B) (2019-2035)
Figure 10.9: Trends and Forecast for the African Anti-Infective Vaccine Market ($B) (2019-2035)
Chapter 11
Figure 11.1: Porter’s Five Forces Analysis of the Global Anti-Infective Vaccine Market
Figure 11.2: Market Share (%) of Top Players in the Global Anti-Infective Vaccine Market (2026)
Chapter 12
Figure 12.1: Growth Opportunities for the Global Anti-Infective Vaccine Market by Type
Figure 12.2: Growth Opportunities for the Global Anti-Infective Vaccine Market by Application
Figure 12.3: Growth Opportunities for the Global Anti-Infective Vaccine Market by Region
Figure 12.4: Emerging Trends in the Global Anti-Infective Vaccine Market
List of Tables
Chapter 1
Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Anti-Infective Vaccine Market by Type and Application
Table 1.2: Attractiveness Analysis for the Anti-Infective Vaccine Market by Region
Table 1.3: Global Anti-Infective Vaccine Market Parameters and Attributes
Chapter 3
Table 3.1: Trends of the Global Anti-Infective Vaccine Market (2019-2026)
Table 3.2: Forecast for the Global Anti-Infective Vaccine Market (2027-2035)
Chapter 4
Table 4.1: Attractiveness Analysis for the Global Anti-Infective Vaccine Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Anti-Infective Vaccine Market (2019-2026)
Table 4.3: Market Size and CAGR of Various Type in the Global Anti-Infective Vaccine Market (2027-2035)
Table 4.4: Trends of Inactivated Vaccines in the Global Anti-Infective Vaccine Market (2019-2026)
Table 4.5: Forecast for Inactivated Vaccines in the Global Anti-Infective Vaccine Market (2027-2035)
Table 4.6: Trends of Conjugate Vaccines in the Global Anti-Infective Vaccine Market (2019-2026)
Table 4.7: Forecast for Conjugate Vaccines in the Global Anti-Infective Vaccine Market (2027-2035)
Table 4.8: Trends of Live/attenuated Vaccines in the Global Anti-Infective Vaccine Market (2019-2026)
Table 4.9: Forecast for Live/attenuated Vaccines in the Global Anti-Infective Vaccine Market (2027-2035)
Chapter 5
Table 5.1: Attractiveness Analysis for the Global Anti-Infective Vaccine Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Anti-Infective Vaccine Market (2019-2026)
Table 5.3: Market Size and CAGR of Various Application in the Global Anti-Infective Vaccine Market (2027-2035)
Table 5.4: Trends of Bacterial Diseases in the Global Anti-Infective Vaccine Market (2019-2026)
Table 5.5: Forecast for Bacterial Diseases in the Global Anti-Infective Vaccine Market (2027-2035)
Table 5.6: Trends of Viral Diseases in the Global Anti-Infective Vaccine Market (2019-2026)
Table 5.7: Forecast for Viral Diseases in the Global Anti-Infective Vaccine Market (2027-2035)
Chapter 6
Table 6.1: Market Size and CAGR of Various Regions in the Global Anti-Infective Vaccine Market (2019-2026)
Table 6.2: Market Size and CAGR of Various Regions in the Global Anti-Infective Vaccine Market (2027-2035)
Chapter 7
Table 7.1: Trends of the North American Anti-Infective Vaccine Market (2019-2026)
Table 7.2: Forecast for the North American Anti-Infective Vaccine Market (2027-2035)
Table 7.3: Market Size and CAGR of Various Type in the North American Anti-Infective Vaccine Market (2019-2026)
Table 7.4: Market Size and CAGR of Various Type in the North American Anti-Infective Vaccine Market (2027-2035)
Table 7.5: Market Size and CAGR of Various Application in the North American Anti-Infective Vaccine Market (2019-2026)
Table 7.6: Market Size and CAGR of Various Application in the North American Anti-Infective Vaccine Market (2027-2035)
Table 7.7: Trends and Forecast for the United States Anti-Infective Vaccine Market (2019-2035)
Table 7.8: Trends and Forecast for the Mexican Anti-Infective Vaccine Market (2019-2035)
Table 7.9: Trends and Forecast for the Canadian Anti-Infective Vaccine Market (2019-2035)
Chapter 8
Table 8.1: Trends of the European Anti-Infective Vaccine Market (2019-2026)
Table 8.2: Forecast for the European Anti-Infective Vaccine Market (2027-2035)
Table 8.3: Market Size and CAGR of Various Type in the European Anti-Infective Vaccine Market (2019-2026)
Table 8.4: Market Size and CAGR of Various Type in the European Anti-Infective Vaccine Market (2027-2035)
Table 8.5: Market Size and CAGR of Various Application in the European Anti-Infective Vaccine Market (2019-2026)
Table 8.6: Market Size and CAGR of Various Application in the European Anti-Infective Vaccine Market (2027-2035)
Table 8.7: Trends and Forecast for the German Anti-Infective Vaccine Market (2019-2035)
Table 8.8: Trends and Forecast for the French Anti-Infective Vaccine Market (2019-2035)
Table 8.9: Trends and Forecast for the Spanish Anti-Infective Vaccine Market (2019-2035)
Table 8.10: Trends and Forecast for the Italian Anti-Infective Vaccine Market (2019-2035)
Table 8.11: Trends and Forecast for the United Kingdom Anti-Infective Vaccine Market (2019-2035)
Chapter 9
Table 9.1: Trends of the APAC Anti-Infective Vaccine Market (2019-2026)
Table 9.2: Forecast for the APAC Anti-Infective Vaccine Market (2027-2035)
Table 9.3: Market Size and CAGR of Various Type in the APAC Anti-Infective Vaccine Market (2019-2026)
Table 9.4: Market Size and CAGR of Various Type in the APAC Anti-Infective Vaccine Market (2027-2035)
Table 9.5: Market Size and CAGR of Various Application in the APAC Anti-Infective Vaccine Market (2019-2026)
Table 9.6: Market Size and CAGR of Various Application in the APAC Anti-Infective Vaccine Market (2027-2035)
Table 9.7: Trends and Forecast for the Japanese Anti-Infective Vaccine Market (2019-2035)
Table 9.8: Trends and Forecast for the Indian Anti-Infective Vaccine Market (2019-2035)
Table 9.9: Trends and Forecast for the Chinese Anti-Infective Vaccine Market (2019-2035)
Table 9.10: Trends and Forecast for the South Korean Anti-Infective Vaccine Market (2019-2035)
Table 9.11: Trends and Forecast for the Indonesian Anti-Infective Vaccine Market (2019-2035)
Chapter 10
Table 10.1: Trends of the RoW Anti-Infective Vaccine Market (2019-2026)
Table 10.2: Forecast for the RoW Anti-Infective Vaccine Market (2027-2035)
Table 10.3: Market Size and CAGR of Various Type in the RoW Anti-Infective Vaccine Market (2019-2026)
Table 10.4: Market Size and CAGR of Various Type in the RoW Anti-Infective Vaccine Market (2027-2035)
Table 10.5: Market Size and CAGR of Various Application in the RoW Anti-Infective Vaccine Market (2019-2026)
Table 10.6: Market Size and CAGR of Various Application in the RoW Anti-Infective Vaccine Market (2027-2035)
Table 10.7: Trends and Forecast for the Middle Eastern Anti-Infective Vaccine Market (2019-2035)
Table 10.8: Trends and Forecast for the South American Anti-Infective Vaccine Market (2019-2035)
Table 10.9: Trends and Forecast for the African Anti-Infective Vaccine Market (2019-2035)
Chapter 11
Table 11.1: Product Mapping of Anti-Infective Vaccine Suppliers Based on Segments
Table 11.2: Operational Integration of Anti-Infective Vaccine Manufacturers
Table 11.3: Rankings of Suppliers Based on Anti-Infective Vaccine Revenue
Chapter 12
Table 12.1: New Product Launches by Major Anti-Infective Vaccine Producers (2019-2026)
Table 12.2: Certification Acquired by Major Competitor in the Global Anti-Infective Vaccine Market

Companies Mentioned

  • Emergent Biodefense Operations Lansing Inc.
  • Sanofi Pasteur
  • Merck & Co.
  • MedImmune LLC
  • Novartis Vaccines & Diagnostics Ltd.
  • Intercell Biomedical
  • MassBiologics
  • Barr Labs
  • Organon Teknika Co.

Methodology

The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:

  • In-depth interviews of the major players in the market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.

Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.

Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

 

Loading
LOADING...